RE:heidelberg pharma using a linkerBet you are right. APC technology is being used to link. Take note of the 25% payment of
€ 332 million. Hope APC is negotiating a piece of this from Heidleberg. Antibodies generated by Magenta's proprietary stem cell platform for up to four exclusive target molecules were used to create new Antibody-Targeted Amanitin Conjugates using Heidelberg Pharmac's ATAC technology. After an initial evaluation phase, Magenta has at least used the opportunity to develop ATAC for a target molecule. After the exclusive license for the worldwide development and marketing rights to the first ATAC program, more will follow. However, this should not happen today and tomorrow, as was to be heard from the business environment. As part of the cooperation, Heidelberg Pharma will be able to award milestone payments totaling € 332 million. A quarter of the amount has now moved closer. Just how little the advance payment made to Heidelberg Pharma for technology access and exclusivity when the cooperation was concluded in March 2018 was announced by the companies, as was the amount of the first milestone payment due now. Apart from that, Magenta pays Heidelberg Pharma for its research achievements.
Magenta Therapeutics Inc. is engaged in bone marrow transplantation research. "There is a great need for targeted conditioning programs prior to bone marrow transplantation. The partnership with Heidelberg Pharma is an important step in the development of our proprietary, targeted antibody-drug conjugates for conditioning, "said Michael Cook, Magenta Therapeutics' Chief Research & Development Officer. Cook refers to amanitin as one of the most promising toxins that the company has to deal with.
As Heidelberg Pharma recently emphasized when presenting the quarterly figures, it has since been possible to transfer the complex synthesis for amanitin to a GMP-certified contract manufacturer. "To the best of our knowledge, this is the world's first and only industrial source of chemically synthesized amanitin, which is essential for our BCMA antibody-drug conjugate HDP-101, but also for our partner projects," said Jan Schmidt-Brand, spokesman for the Board member and CFO of Heidelberg Pharma AG. Contract manufacturer is the Carbogen Amcis AG in Switzerland.